Michael E D West - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

Michael E D West

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

Tissue Engineering. Part A|October 24, 2018

Bone Marrow-Derived Macrophages Enhance Vessel Stability in Modular Engineered TissuesMichael E D West, Elana J B Sefton, Michael V Sefton

Annals of Biomedical Engineering|October 10, 2014

In vivo remodelling of vascularizing engineered tissuesM Dean Chamberlain, Michael E D West, Gabrielle C Lam, et al.

Blood Cancer Journal|April 1, 2026

Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United StatesShaji Kumar, Katja C Weisel, Paul Spin, et al.

Blood Cancer Journal|March 26, 2026

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelomaShaji Kumar, Sundar Jagannath, Katja C Weisel, et al.

Pageof 1

Search research articles

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

Tissue Engineering. Part A|October 24, 2018

Bone Marrow-Derived Macrophages Enhance Vessel Stability in Modular Engineered TissuesMichael E D West, Elana J B Sefton, Michael V Sefton

Annals of Biomedical Engineering|October 10, 2014

In vivo remodelling of vascularizing engineered tissuesM Dean Chamberlain, Michael E D West, Gabrielle C Lam, et al.

Blood Cancer Journal|April 1, 2026

Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United StatesShaji Kumar, Katja C Weisel, Paul Spin, et al.

Blood Cancer Journal|March 26, 2026

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelomaShaji Kumar, Sundar Jagannath, Katja C Weisel, et al.

Pageof 1